Sharemaestro company-news research for Vericel Corp Ord (VCEL), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest VCEL news and sentiment
Vericel Corp Ord
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
2 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone59/100
→
Published 30-day score50/100
Latest source headline
Vericel (VCEL) Stock Looks Fully Priced After A 31% Gain
Simply Wall St. · 26 Sep 2026 22:06
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
2 current stories are mapped specifically to VCEL.
What limits the score
Only 1 publisher currently contribute to the measured read.
The stories agree, but freshness-weighted evidence is only 0.022.
Confidence is 15/100, below the threshold for a firm score.
50/100
News scoreEarly balanced news score
15/100
Confidencethin evidence
78%/100
Company news2 company stories
100/100
Story agreement0/100 difference
News history
Daily score and story count over 30 days
16 Sep01 Oct15 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.022 after freshness weightingSource breadth20
1 independent publishersCompany relevance78
share tied directly to this companyFreshness4
recency-weighted evidenceAgreement100
how closely stories agreePublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks21 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202650USD 40.1-0.1%
02 Oct 202650USD 40.15+1.1%
25 Sep 202650USD 39.71-0.8%
18 Sep 202650USD 40.02+4.4%
11 Sep 202650USD 38.34-4.6%
04 Sep 202650USD 40.19-1.9%
28 Aug 202651USD 40.95-4.1%
21 Aug 202654USD 42.68-3.4%
Provisional evidence
News subjects
What is shaping the score
Balance sheet591 stories · 50%
Market update501 stories · 50%
Source mix
Where the evidence comes from
Simply Wall St.591 stories · 50%
GuruFocus501 stories · 50%
Recurring subjects
Subjects appearing most often
Earnings2Share Price1Life Sciences1Intrinsic Value1Free Cash Flow1Dcf1Cash Flow1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
07 May50 neutral11 Oct 16:51
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 11 Oct 16:51 | 50 | -1 | 16/100 (-12) | 2 (-2) | Provisional |
| 26 Sep 23:59 | 51 | +1 | 28/100 (+13) | 4 (-1) | Provisional |
| 16 Sep 23:59 | 50 | +0 | 15/100 (0) | 5 (-8) | Provisional |
| 08 Sep 23:59 | 50 | +0 | 15/100 (0) | 13 (+1) | Provisional |
| 07 Sep 23:59 | 50 | -4 | 15/100 (-13) | 12 (-27) | Provisional |
| 21 Aug 23:59 | 54 | +0 | 28/100 (-3) | 39 (0) | Provisional |
| 18 Aug 23:59 | 54 | +0 | 31/100 (-3) | 39 (0) | Provisional |
| 15 Aug 23:59 | 54 | +0 | 34/100 (+3) | 39 (-1) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 2 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Balance sheet1 story
0.0%100.0%
Each side uses the same scale: 0–100.0% of the retained directional evidence.
Where the influence comes from
100.0%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
59/100 tone
Balance sheet
Vericel (VCEL) Stock Looks Fully Priced After A 31% Gain
Vericel has delivered a solid 31.4% share price gain over the past year, which naturally puts a spotlight on whether that move lines up with the cash the business is expected to generate. With the stock last closing at US$39.71, the key issue for you is whether that market value can be re…
100% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Vericel has delivered a solid 31.4% share price gain over the past year, which naturally puts a spotlight on whether that move lines up with the cash the business is expected to generate. With the stock last closing at US$39.71, the key issue for you is whether that market value can be reconciled with what its cash flows imply through a Discounted Cash Flow (DCF) lens. The 31.4% one year return has rewarded existing holders, so any fresh money coming in now needs a clear view on what the underlying cash generation can support. Vericel's ability to turn its current product portfolio and operati
- Published
- 26 Sep 2026 22:06
- News subject
- Balance sheet
- Why this score
- Positive financial language
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 37/100
- 30-day weight
- 100% of directional evidence · 18.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 2 consolidated
Cash FlowDcfEarningsFree Cash FlowIntrinsic ValueShare Price
—Unscored
Market updateNot used in direction
Vericel Corporation at Morgan Stanley Global Healthcare Conference Transcript
This article provides the transcript of Vericel Corporation's presentation at the Morgan Stanley Global Healthcare Conference on September 15, 2026. CEO Nick Colangelo and CFO Joe Mara discussed Macy, their lead product for cartilage repair, including updates on its international launch p…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides the transcript of Vericel Corporation's presentation at the Morgan Stanley Global Healthcare Conference on September 15, 2026. CEO Nick Colangelo and CFO Joe Mara discussed Macy, their lead product for cartilage repair, including updates on its international launch preparations and a trial for ankle application. The conference provided an opportunity to highlight ongoing initiatives driving the company's growth.
- Published
- 16 Sep 2026 15:56
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 28.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsLife Sciences
Earlier company news
VCEL news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 62 older VCEL headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to VCEL, but the headline and available text are not mainly about Vericel Corp Ord. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
21Aug 2026
Provider mentionNot included in score
Madison Asset Management LLC Acquires Shares of 50,116 Vericel Corporation $VCEL
Madison Asset Management LLC has acquired 50,116 shares of Vericel Corporation (NASDAQ:VCEL), valued at approximately $2.23 million, representing a new position for the firm. Other institutional investors like BlackRock Inc. and TimesSquare Capital Management LLC also increased their stak…
Article detailsWhy it was excluded
Madison Asset Management LLC has acquired 50,116 shares of Vericel Corporation (NASDAQ:VCEL), valued at approximately $2.23 million, representing a new position for the firm. Other institutional investors like BlackRock Inc. and TimesSquare Capital Management LLC also increased their stakes. The article also details recent insider stock sales by Vericel's CFO and another insider, stock performance data, and updated analyst ratings for VCEL.
- Published
- 21 Aug 2026 11:06
- Provider record
- alphavantage
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
18Aug 2026
Provider mentionNot included in score
TimesSquare Capital Management LLC Invests $24.46 Million in Vericel Corporation $VCEL
TimesSquare Capital Management LLC has invested $24.46 million in Vericel Corporation (VCEL), acquiring 549,846 shares. Other institutional investors have also increased their holdings, while company insiders sold shares. Analyst sentiment is generally positive, with a "Moderate Buy" cons…
Article detailsWhy it was excluded
TimesSquare Capital Management LLC has invested $24.46 million in Vericel Corporation (VCEL), acquiring 549,846 shares. Other institutional investors have also increased their holdings, while company insiders sold shares. Analyst sentiment is generally positive, with a "Moderate Buy" consensus and an average price target of $58.40, following strong quarterly earnings that exceeded expectations.
- Published
- 18 Aug 2026 10:42
- Provider record
- alphavantage
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
13Aug 2026
Provider mentionNot included in score
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
MediWound Ltd. EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid® Second Quarter Revenue of $3.1 Million; Full-Year 2026 Revenue …
Article detailsWhy it was excluded
MediWound Ltd. EscharEx® Phase III VALUE Trial Advancing; Interim Assessment and Enrollment Completion Expected by End of First Quarter 2027 Master Services Agreement Signed with Vericel Under its BARDA Contract for NexoBrid® Second Quarter Revenue of $3.1 Million; Full-Year 2026 Revenue Guidance of $24–26 Million Reaffirmed Conference Call Today at 8:30 a.m. Eastern Time YAVNE, Israel, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June
- Published
- 13 Aug 2026 12:00
- Provider record
- eodhd
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
- Duplicates
- 1 consolidated
BiotechClinical TrialsEarningsFinancial ResultsFourth QuarterGuidance
10Aug 2026
Provider mentionNot included in score
3 Major Earnings Winners You May Have Missed
This article highlights three companies, Vericel (VCEL), Xenia Hotels & Resorts (XHR), and International Paper (IP), that posted notable earnings results but may have been overlooked during earnings season. Vericel, a biotech firm, showed strong financials and raised its revenue guidance,…
Article detailsWhy it was excluded
This article highlights three companies, Vericel (VCEL), Xenia Hotels & Resorts (XHR), and International Paper (IP), that posted notable earnings results but may have been overlooked during earnings season. Vericel, a biotech firm, showed strong financials and raised its revenue guidance, while Xenia Hotels & Resorts, a REIT, improved key metrics despite a net loss from an impairment charge. International Paper, undergoing transformation, demonstrated operational improvements and box volume growth despite missing revenue estimates.
- Published
- 10 Aug 2026 14:11
- Provider record
- alphavantage
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
- Duplicates
- 1 consolidated
EarningsLife SciencesReal EstateFinancial MarketsManufacturing
14Jul 2026
Provider mentionNot included in score
Source lookup
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
Article detailsWhy it was excluded
- Published
- 14 Jul 2026 21:14
- Provider record
- snapshot
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
- Duplicates
- 1 consolidated
27Jun 2026
Provider mentionNot included in score
Source lookup
15,000-Share Option Exercise Reported for Vericel (NASDAQ: VCEL)
Article detailsWhy it was excluded
- Published
- 27 Jun 2026 05:44
- Provider record
- snapshot
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
- Duplicates
- 1 consolidated
07May 2026
Provider mentionNot included in score
Burn care sales surge 91% as Vericel lifts 2026 revenue target
Article detailsWhy it was excluded
- Published
- 7 May 2026 08:00
- Provider record
- google_news
- Use in sentiment
- Not scored
- Reason
- Company is not the main subject
- Duplicates
- 1 consolidated
How the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.